Alzamend Neuro Announces Reverse Stock Split [Yahoo! Finance]
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
Alzamend Neuro, Inc. (ALZN)
Company Research
Source: Yahoo! Finance
company focused on developing novel products for the treatment of Alzheimer's disease (" Alzheimer's "), bipolar disorder (" BD "), major depressive disorder (" MDD ") and post-traumatic stress disorder (" PTSD "), today announced that Alzamend's board of directors approved a one-for-ten reverse stock split of Alzamend's common stock (" Common Stock ") that will be effective in the State of Delaware at 12:01 a.m. Eastern Time on July 16, 2024. Beginning with the opening of trading on July 16, 2024, the Company's Common Stock will trade on The Nasdaq Capital Market on a split-adjusted basis under the Company's existing trading symbol "ALZN". The new CUSIP number for the Common Stock will be 02262M506. The reverse stock split is part of the Company's plan to regain compliance with the Minimum Bid Price Requirement of $1.00 per share required to maintain continued listing on The Nasdaq Capital Market, among other benefits. The reverse stock split affects all issued and outstanding shar
Show less
Read more
Impact Snapshot
Event Time:
ALZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALZN alerts
High impacting Alzamend Neuro, Inc. news events
Weekly update
A roundup of the hottest topics
ALZN
News
- Alzamend Neuro Issues Letter to StockholdersBusiness Wire
- Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress DisorderBusiness Wire
- Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder Business Wire
- Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar DisorderBusiness Wire
- Alzamend Neuro partners with Mass General for Alzheimer's treatment trial [Yahoo! Finance]Yahoo! Finance
ALZN
Sec Filings
- 8/14/24 - Form 4
- 8/1/24 - Form 4
- 7/31/24 - Form 8-K
- ALZN's page on the SEC website